Carvedilol: Just another beta-blocker or a powerful cardioprotector?

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 6, Issue 4, 2006, Pages 257-266

  Carreira, R S ^a   Monteiro, P ^a   Goncalves L M ^a   Providencia L A ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Antioxidant cardioprotection; Carvedilol; Ischemia reperfusion; Mitochondrial permeability transition; Reactive oxygen species

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTIOXIDANT; ASCORBIC ACID; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BM 910228; CARVEDILOL; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; METOPROLOL TARTRATE; PLACEBO; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TIMOLOL;

ADRENERGIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM HOMEOSTASIS; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL AGGREGATION; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG WITHDRAWAL; ENERGY YIELD; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT; STRUCTURE ANALYSIS;

EID: 33845394025     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152906779010746     Document Type: Article

References (124)

1. Gill, C., Mestril, R, Samali, A. Losing heart: the role of apoptosis in heart disease - a novel therapeutic target? FASEB J., 2002, 16, 135-146.
2. Lesnefsky, E.J., Moghaddas, S., Tandler, B., Kerner, J., Hoppel, C.L. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart Wine. J. Mol. Cell Cardiol., 2001, 33, 1065-1089.
3. St-Pierre, J., Brand, M.D., Boutilier, R.G. Mitochondria as ATP Consumers: Cellular Treason in Anoxia. Proc. Natl. Acad. Sci. USA, 2000, 97(15), 8670-8674.
4. Rego, A.C., Vesce, S., Nicholls, D.G. The mechanism of mitochondrial membrane potential retention following release of cytochrome c in apoptotic GT1-7 neural cells. Cell Death Differ., 2001, 8, 995-1003.
5. Crompton, M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J., 1999, 341, 233-249.
6. + exchange and its inhibition in cardiac ischemia and reperfusion. Basic Res. Cardiol., 1993, 88(5), 443-455.
7. + Exchanger. Am. J. Physiol., 1999, 276, H1581-H1590.
8. Grover, G.J., Dzwonczyk, S., Sleph, P.G. Ruthenium red improves postischemic contractile function in isolated rat hearts. J. Cardiovasc. Pharm., 1990, 16, 783-789.
9. Avkiran, M. Rational Basis for Use of Sodium-Hydrogen Exchange Inibitors in Myocardial Ischemia. Am. J. Cardiol., 1999, 83, 10G-18G.
10. Nohl, H. Generation of superoxide radicals as byproduct of cellular respiration. Ann. Biol. Clin. (Paris), 1994, 52, 199-204.
11. Radi, R., et al. Free radical damage to mitochondria. In Mitochondria and Free Radicals in Neurodegenerative Diseases; Beal, M.F, Howell, N, Bodis-Wollner, I, Ed; Wiley-Liss, Inc: New York, 1997, pp. 57-89.
12. Das, D.K., George, A., Liu, X.K., Rao, P.S. Detection of hydroxyl radical in the mitochondria of ischemic-reperfused myocardium by trapping with salicylate. Biochem. Biophys. Res. Commun., 1989, 165, 1004-1009.
13. Becker, L.B., Hoek, T.L.V., Shao, Z.H., Li, C.Q., Schumacker, P.T. Generation of Superoxide in Cardiomyocytes During Ischemia Before Reperfusion. Am. J. Physiol., 1999, 277, H2240-H2246.
14. Downey, J.M. Free Radical and Their Involvement During Long-Term Myocardial Ischemia and Reperfusion. Annu. Rev. Physiol., 1990, 52, 487-504.
15. Ferrari, R. The role of mitochondria in ischemic heart disease. J Cardiovasc. Pharmacol., 1996, 28 (Suppl 1), S1-S10.
16. Tien, M., Svingen, B.A., Aust, S.D. Superoxide dependent lipid peroxidation. Fed. Proc., 1981, 40, 179-182.
17. Dhalla, N.S., Elmoselhi, A.B., Hata, T., Makino, N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc. Res., 2000, 47, 446-456.
18. Siveski-Iliskovic, N., Hill, M., Chow, D.A., Singal, P.K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 1995, 91, 10-15.
19. Yue, T.L., Ma, X.L., Wang, X., Romanic, A.M., Liu, G.L., Louden, C., Gu, J.L., Kumar, S., Poste, G., Ruffolo, R.R., Jr, Feuerstein, G.Z. Possible involvement of stress activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ. Res., 1998, 82, 166-174.
20. Griffiths, E.J. Mitochondria-potential role in cell life and death. Cardiovasc. Res., 2000, 46(1), 24-27.
21. Petronilli, V., Constantini, P., Scorrano, L., Colonna, R., Passamonti, S., Bernardi, P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. J. Biol. Chem., 1994, 269, 16638-16642.
22. Chernyak, B.V., Bernardi, P. The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur. J. Biochem., 1996, 238, 623-630.
23. Fagian, M.M., Pereira-da-Silva, L., Martins, I.S., Vercesi, A.E. Membrane protein thiol cross-linking associated with the permeabilization of the inner mitochondrial membrane by Ca2+ plus prooxidants. J. Biol. Chem., 1990, 265(32), 19955-19960.
24. Weiss, J.N., Korge, P., Honda, H.M., Ping, P. Role of the mitochondrial permeability transition in myocardial disease. Circ. Res., 2003, 93(4), 292-301.
25. Bernardi, P. Mitochondrial transport of cations: channels exchangers and permeability transition. Physiol. Rev., 1999, 79, 1127-1155.
26. Halestrap, A.P., Kerr, P.M., Javadov, S., Woodfield, K-Y. Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim. Biophys. Acta, 1998, 1366, 79-94.
27. Frishman, W.H. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: Current concepts. Circulation, 1983, 67 (suppl. 1), 111-118.
28. Frishman, W.H. Clinical Pharmacology of the β-Adrenoreceptor Blocking Drugs, 2nd ed. Norwalk, CT, Appleton-Century-Crofts, 1984.
29. Braunwald, E., Muller, J.E., Kloner, R.A., Maroko, P. Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction. Am. J.Med., 1983, 74, 113-123.
30. Ganz, P., Braunwald, E. Coronary blood flow and myocardial ischemia. In Heart Disease - A Textbook of Cardiovascular Medicine, Braunwald, E., Ed.; W B Saunders: Philadelphia, 2000, pp. 1265-1285.
31. Reiter, M.J. Cardiovascular Drug Class Specificity: β-Blockers. Prog. Cardiovasc. Dis., 2004, 47(1), 11-33.
32. Frishman, W.H., Furberg, C.D., Friedewald, W.T. Beta-Adrenergic blockade for survivors of acute myocardial infarction. N. Engl. J. Med., 1984, 310, 830-837.
33. Nayler, W.G., Fassold, E., Yepez, C. Pharmacological protection of mitochondrial function in hypoxic heart muscle: effect of verapamil, propranolol, and methylprednisolone. Cardiovasc. Res., 1978, 12, 152-161.
34. Ogawa, T., Hieda, N., Sugiyama, S., Ito, T., Satake, T., Ozawa, T. Cardioprotective and antiarrythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia. Heart Vessels, 1989, 5, 10-16.
35. Ogawa, T., Sugiyama, S., Hieda, N., Ito, T., Satake, T., Ozawa, T. Biochemical and morphological changes in myocardium during coronary occlusion and reperfusion in canine hearts: effects of propranolol on myocardial damage. Cardiovasc. Res., 1989, 23, 417-423.
36. Oliveira, P.J., Rolo, A.P., Sardão, V.A., Monteiro, P., Gonçalves, L., Providencia, L.A., Palmeira, C.M., Moreno, A.J. Advantages in the use of carvedilol versus propranolol for the protection of cardiac mitochondrial function. Rev. Port. Cardiol., 2004, 23(10), 1291-1298.
37. Mak I.T., Weglicki, W,B. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ. Res., 1990, 66(5), 1449-1452.
38. Iwai, T., Tanonaka, K., Kasahara, S., Inoue, R., Takeo, S. Protective effect of propranolol on mitochondrial function in the ischaemic heart. Br. J. Pharmacol., 2002, 136(3), 472-480.
39. Quinn, P.J., Crutcher, E.C. The action of beta-adrenoceptor antagonists on rat heart mitochondrial function in vitro: a comparison of propranolol, timolol, and atenolol. Cardiovasc. Res., 1984, 18(4), 212-219.
40. Almotrefi, A.A., Dzimiri, N. Effects of beta-adrenoceptor blockers on mitochondrial ATPase activity in guinea pig heart preparations. Eur. J. Pharmacol., 1992, 215(2-3), 231-236.
41. Lu, H.R., Vandeplassche, G., Wouters, L., Flameng, W., Borgers, M. Effects of beta-adrenoceptor antagonists on cardiac function in ischemic-reperfused myocardium of the isolated working rabbit heart. Eur. J. Pharmacol., 1990, 184(1), 65-74.
42. Vandeplassche, G., Lu, H.R., Wouters, L., Flameng, W., Borgers, M. Normothermic ischemic cardiac arrest in the isolated working rabbit heart: effects of dl-nebivolol and atenolol. Basic Res. Cardiol., 1991, 86(1), 21-31.
43. Monteiro, P., Duarte, A.I., Moreno, A., Gonçalves, L.M., Providencia, L.A. Carvedilol improves energy production during acute global myocardial ischaemia. Eur. J. Pharmacol., 2003, 482(1-3), 245-253.
44. Cleland, J.G., McGowan, J. Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. J. Cardiovasc. Pharmacol., 1999, 33(Suppl. 3), S17-S29.
45. Cleland, J.G., McGowan, J., Clark, A., Freemantle, N. The evidence for beta-blockers in heart failure. BMJ, 1999, 318, 824-825.
46. Colucci, W.S., Packer, M., Bristow, M.B., Gilbert, E.M., Cohn, J.N., Fowler, M.B., Krueger, S.K., Hershberger, R., Uretsky, B.F., Bowers, J.A., Sackner-Bernstein, J.D., Young, S.T., Holcslaw, T.L., Lukas, M.A. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 1996, 94, 2800-2806.
47. Dargie, H.J., Colucci, W.S., Ford, I., Lopez-Sendon, J.L., Remme, W.J., Sharpe, N. CAPRICORN - a study of carvedilol post myocardial infarction. Cardiovasc. Drugs Ther., 1999, 13, 24.
48. Dargie, H.J. Design and methodology of the CAPRICORN trial-a randomized double-blind placebo-controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail., 2000, 2, 325-332.
49. Dargie, H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet, 2001, 357, 1385-1390.
50. Feuerstein, G., Yue, T.L., Ma, X., Ruffolo, R.R. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog. Cardiovasc. Dis., 1998, 41, 17-24.
51. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., Shusterman, N.H. For the US Carvedilol Heart Failure Society Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med., 1996, 334, 1349-1355.
52. Packer, M., Coats, A.J., Fowler, M.B., Katus, H.A., Krum, H., Mohacsi, P., Rouleau, J.L., Tendera, M., Castaigne, A., Roecker, E.B., Schultz, M.K., DeMets, D.L. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med., 2001, 344(22), 1651-1658.
53. Dunn, C.J., Lea, A.P., Wagstall, A.J. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs, 1997, 54, 161-185.
54. Feuerstein, G.Z., Ruffolo Jr., R.R. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J., 1995, 16(Suppl. F), 38-42.
55. Noguchi, N., Nishino, K., Niki, E. Antioxidant action of the anti-hypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol., 2000, 59, 1069-1076.
56. Ryan, T.J., Antman, E.M., Brooks, N.H., Califf, R.M., Hillis, H.D., Hiratzka, L.F., Rapaport, E., Riegel, B., Russell, R.O., Smith, III, E.E., Weaver, W.D. ACC/AHA guidelines of the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction), 1999.
57. Lysko, P.G., Lysko, K.A., Webb, C.L., Feuerstein, G. Neuroprotective effects of carvedilol, a new antihypertensive, at the N-methyl-D-aspartate receptor. Neurosci. Lett., 1992, 148(1-2), 34-38.
58. Lysko, P.G., Lysko, K.A., Yue, T.L., Webb, C.L., Gu, J.L., Feuerstein, G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke, 1992, 23(11), 1630-1635.
59. Yue, T.L., Lysko, P.G., Barone, F.C., Gu, J.L., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvedilol, a new antihypertensive drug with unique antioxidant activity: Potential role in cerebroprotection. Ann. N. Y. Acad. Sci., 1994, 738, 230-242.
60. Feuerstein, G.Z., Yue,T.L., Cheng, H.Y., Ruffolo, R.R. Jr. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: Potential relevance of antioxidant activity. J. Hypertens. Suppl., 1993, 11(4), S41-S48.
61. Sugawara, H., Tobise, K., Kikuchi, K. Antioxidants effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Hypertens: Res., 1996, 19, 223-228.
62. Yue, T.L., Mckenna, P.J., Gu, J.L., Cheng, H.Y., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension, 1993, 22(6), 922-928.
63. Yue, T.L., McKenna, P.J., Gu, J.L., Cheng, H.Y., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvedilol, a new vasodilating b adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-oxidase and neutrophils. Candiovasc. Res., 1994, 28(3), 400-406.
64. Yue, T.L., McKenna, P.J., Lysko, P.G., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis, 1992, 97(2-3), 209-216.
65. Maggi, E., Marchesi, E., Covini, D., Negro, C., Perani, G., Bellomo, G. Protective effects of carvedilol, a vasodilating b-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J. Cardiovasc. Pharmacol., 1996, 27(4), 532-538.
66. Bristow, M.R. Mechanism of action of beta-blocking agents in heart failure. Am. J. Cardiol., 1997, 80(11A), 26L-40L.
67. Bristow, M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation, 2000, 101, 558-569.
68. Packer, M. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice. Prog. Cardiovasc. Dis., 1998, 41(Suppl. 1), 39-52.
69. Metra, M., Nodari, S., D'Aloia, A., Bontempi, L., Boldi, E., Dei Cas., L. A rationale for the use of beta-blockers as standard treatment for heart failure. Am. Heart J., 2000, 139, 511-521.
70. Metra, M., Nodari, S., Dei Cas, L. Beta-blockade in heart failure: Selective versus nonselective agents. Am. J. Cardiovasc. Drugs, 2001, 1, 3-14.
71. Hall, J.A., Petch, M.A., Brown, M.J. Intracoronary injections of salbutamol demonstrate the presence of functional beta 2- adrenoceptors in the human heart. Circ. Res., 1989, 65, 546-553.
72. Newton, G.E., Parker, J.D. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation, 1996, 94, 353-358.
73. Du, X.J., Autelitano, D., Dilley, R.J., Wang, B., Dart, A.M., Woodcock, E.A. β 2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation, 2000, 101, 71-77.
74. Billman, G.E., Castillo, L.C., Hensley, J., Hohl, C.M., Altschuld, R.A. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation. In vivo and in vitro evidence for enhanced sensitivity to beta 2-adrenergic stimulation in animals susceptible to sudden death. Circulation, 1997, 96, 1914-1922.
75. Stroe, A.F., Gheorghiade, M. Carvedilol: Beta-blockade and beyond. Rev. Cardiovasc. Med., 2004, 5(Suppl. 1),S18-S27.
76. Yue, T.L., Feuerstein, G.Z. Carvedilol, a new vasodilator and b-adrenoceptor antagonists, inhibits oxygen radical mediated lipid peroxidation in swine ventricular membranes. Pharmacol. Commun., 1992, 1, 27-35.
77. Yue, T.L., Cheng, H.Y., Lysko, P.G., McKenna, P.J. Feuerstein, R., Gu, J.L., Lysko, K.A., Davis, L.L., Feuerstein, G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther., 1992, 263(1), 92-98.
78. Yue, T.L., Wang, X., Gu, J.L., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J. Pharmacol. Exp. Ther., 1995, 273, 1442-1449.
79. Tadolini, B., Franconi, F. Carvedilol inhibition of lipid peroxidation. A new antioxidative mechanism. Free Radic. Res., 1998, 29, 377-387.
80. Kramer, J.H., Weglicki, W.B. A hydroxylated analog of the b-adrenoreceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radic. Biol. Med., 1996, 21, 813-825.
81. Cargnoni, A., Ceconi, C., Bernocchi, P., Boraso, A., Parrinello, G., Curello, S., Ferrari, R. Reduction of Oxidative Stress by Carvedilol: Role in Maintenance of Ischaemic Myocardium Viability. Cardiovasc. Res., 2000, 47(3), 556-566.
82. Rossig, L., Haendeler, J., Mallat, Z., Hugel, B., Freyssinet, J.M., Tedgui, A., Dimmeler, S., Zeiher, A.M. Congestive Heart Failure Induces Apoptosis: Protective Role of Carvedilol. J. Am. Coll. Cardiol., 2000, 36, 2081-2089.
83. Santos, D.J.S.L., Moreno, A.J.M. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228. Biochem. Pharmacol., 2001, 61, 155-164. .
84. Yue, T.L., McKenna, P.J., Ruffolo, R.R.Jr., Feuerstein, G. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator anti-hypertensive drug, inhibits superoxide release from human neutrophils. Eur. J. Pharmacol., 1992, 214(2-3), 277-280.
85. Moreno, A.J.M., Santos, D.J.S.L., Palmeira, C.M. Ischemic Heart Disease: The Role of Mitochondria - Carvedilol Prevents Lipid Peroxidation of Mitochondrial Membranes. Rev. Port. Cardiol., 1998, 17, II-63-II-77.
86. Oliveira, P.J., Marques, M.P., Batista de Carvalho, L.A., Moreno, A.J. Effects of carvedilol on isolated heart mitochondria: evidence for a protonophoretic mechanism. Biochem. Biophys. Res. Commun., 2000, 276(1), 82-87.
87. Oliveira, P.J., Rolo, A.P., Sardao, V.A., Coxito, P.M., Palmeira, C.M., Moreno, A.J. Carvedilol in heart mitochondria: protonophore or opener of the mitochondrial K(ATP) channels? Life Sci., 2001, 69(2), 123-132.
88. Korshunov, S.S., Skulachev, V.P., Starkov, A.A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett., 1997, 416, 15-18.
89. Starkov, A.A. Mild uncoupling of mitochondria. Biosci. Rep., 1997, 17(3), 273-279.
90. Brand, M.D., Buckingham, J.A., Esteves, T.C., Green, K., Lambert, A.J., Miwa, S., Murphy, M.P., Pakay, J.L., Talbot, D.A., Echtay, K.S. Mitochondrial superoxide and aging: uncoupling-protein activity and superoxide production. Biochem. Soc. Symp., 2004, 71, 203-213.
91. Brookes, P.S. Mitochondrial H(+) leak and ROS generation: an odd couple. Free Radic. Biol. Med., 2005, 38(1), 12-23.
92. Abreu, R.M., Santos, D.J., Moreno, A.J. Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. J. Pharmacol. Exp. Ther., 2000, 295(3), 1022-1030.
93. Shan, K., Lincoff, A.M., Young, J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med., 1996, 125, 47-58.
94. Santos, D.L., Moreno, A.J.M., Leino, R.L., Froberg, M.K., Wallace, K.B. Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy. Toxicol. Appl. Pharmacol., 2002, 185, 218-227.
95. Mott, M.G. Anthracycline cardiotoxicity and its prevention. Ann. N. Y. Acad. Sci., 1997, 824, 221-228.
96. Olson, R.D., Mushlin, P.S. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J., 1990, 4, 3076-3086.
97. Singal, P.K., Iliskovic, N., Li, T., Kumar, D. Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB J., 1997, 11, 931-936.
98. Singal, P.K., Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 1998, 339, 900-905.
99. Allen, A. The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol., 1992, 19, 529-542.
100. Lefrak, E.A., Pitha, J., Rosenheim, S., Gottlieb, J.A. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer (Phila.), 1973, 32(2), 302-314.
101. Singal, P.K, Deally, C.M.R, Weinberg, L.E. Subcellular effects of Adriamycin in the heart: a concise review. J. Mol. Cell Cardiol., 1987, 19, 817-828.
102. Cassidy, S.C., Chan, D.P., Rowland, D.G., Allen, H.D. Effects of doxorubicin on diastolic function, contractile reserve, and ventricular-vascular coupling in piglets. Pediatr. Cardiol., 1998, 19(6), 450-457.
103. Saeki, K., Obi, I., Ogiku, N., Shigekawa, M., Imagawa, T., Matsumoto, T. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci., 2002, 70(20), 2377-2389.
104. Demant, E.J.F. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem. Pharmacol., 1991, 41, 543-552.
105. Palmeira, C.M., Serrano, J., Kuehl, D.W., Wallace, K.B. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim. Biophys. Acta, 1997, 1321, 101-106.
106. Mimnaugh, E.G., Trush, M.A., Bhatnagar, M., Gram, T.E. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem. Pharmacol., 1985, 34, 847-856.
107. Doroshow, J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res., 1983, 43, 460-472.
108. Kang, Y.J., Chen, Y., Yu, A., Voss-McCowan, M., Epstein, P.N. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Invest., 1997, 100(6), 1501-1506.
109. Childs, A.C., Phaneuf, S.L. Dirks, A.J., Phillips, T., Leeuwenburgh, C. Doxorubucicn treatment in vivo causes cytochrome c release and cardiomyocyte Apoptosis, as well as increased mitochondrial efficiency, superoxide Dismutase activity, and bcl-2:bax ratio. Cancer Res., 2002, 62(16), 4592-4598.
110. Nohl, H. A novel superoxide radical generator in heart mitochondria. FEBS Lett., 1987, 214, 269-273.
111. Nohl, H., Gille, L., Staniek, K. The Exogenous NADH Dehydrogenase of Heart Mitochondria Is the Key Enzyme Responsible for Selective Cardiotoxicity of Anthracyclines. Z. Naturforsch., 1998, 53(3-4), 279-285.
112. Sokolove, P.M., Shinaberry, R.G. Na+-independent release of Ca2+ from rat heart mitochondria-induction by adriamycin aglycone. Biochem. Pharmacol., 1988, 37, 803-812.
113. Solem, L.E., Henry, T.R., Wallace, K.B. Disruption of mitochondrial calcium homeostasis in vivo following chronic doxorubicin administration. Toxicol. Appl. Pharmacol., 1994, 129, 214-222.
114. Solem, L.E., Heller, L.J., Wallace, K.B. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J. Mol. Cell Cardiol., 1996, 28, 1023-1032.
115. Zhou, S., Heller, L.J., Wallace, K.B. Interference with calcium dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol. Appl. Pharmacol., 2001, 175, 60-67.
116. Zhou, S., Starkov, A., Froberg, M.K., Leino, R.L., Wallace, K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res., 2001, 61, 771-777.
117. Oliveira, P.J., Santos, D.J., Moreno, A.J.M. Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria. Arch. Biochem. Biophys., 2000, 374(2), 279-295.
118. Oliveira, P.J., Bjork, J.A., Santos, M.S., Leino, R.L., Froberg, M.K., Moreno, A.J.M., Walace, K.B. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol., 2004, 200, 159-168.
119. Matsui, H., Morishima, I., Numaguchi, Y., Toki, Y., Okumura, K., Hayakawa, T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci., 1999, 65(12), 1265-1274.
120. Mukai, Y., Yoshida, T., Nakaike, R., Mukai, N., Iwato, K., Kyo, T., Kaseda, S. Five Cases of Anthracycline-Induced Cardiomyopathy Effectively Treated with Carvedilol. Intern. Med., 2004, 43(11), 1087-1088.
121. Jonsson, O., Behnam-Motlagh, P., Persson, M., Henriksson, R., Grankvist, K. Increase in Doxorubicin Cytotoxicity by Carvedilol Inhibition of P-Glycoprotein Activity. Biochem. Pharmacol., 1999, 58, 1801-1806.
122. Bristow, M.R., Gilliert, E.M., Abraham, W.T., Adams, K.F., Fowler, M.B., Hershberger, R.E., Kubo, S.H., Narahara, K.A., Ingersoll, H., Krueger, S., Young, S., Shusterman, N. Congestive heart failure/myocardial disease: carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Clinical investigation and reports. Circulation, 1996, 94(11), 2807-16.
123. Packer, M., Fowler, M., Rouleau, J., Tendera, M., et al. COPERNICUS (Carvedilol Prospective Randomixed Cumilative Survival Trial). A multicenter randomized double-blind, placebo-controlled study to determine the effect of carvedilol on mortality in severe congestive heart failure. Cardiovasc. Drugs Ther., 1999, 13, 24.
124. Poole-Wilson, P.A., Swedberg, K., Cleland, J.G., Di Lenarda, A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., Remme, W.J., Torp-Pedersen, C., Scherhag, A., Skene, A. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003, 362(9377), 7-13.